[ad_1]
According to a study published in the open access journal on July 30, increased brand competition is unlikely to lower branded drug prices in the United States. PLOS Medicine by Ameet Sarpatwari of Brigham and Women's Hospital and Harvard Medical School, and their colleagues.
US spending on prescription drugs has risen sharply over the past decade, due to rising introductory prices for new drug products and systematic increases in prices of old prescription drugs. origin. It has been proposed to promote greater competition between brands, which occurs between the brand name drugs indicated for the same problem, to cope with high drug prices. Yet, there are many examples of price increases following the introduction of brand competition, calling into question its effectiveness in the pharmaceutical market. In order to better understand the economic impact of brand competition, Sarpatwari and his colleagues systematically reviewed the peer-reviewed literature to badyze the influence of the new drug market on the prices of drugs of the same clbad for drugs. patients with the same indications. They searched PubMed and EconLit for original studies of brand competition in the US market published in English between 1990 and April 2019, and found 10 studies evaluating a wide range of drug clbades.
None of the 10 studies found that competition between brands of medications lowered the list price of existing branded drugs in one clbad. The findings of two studies suggest, however, that such competition may help to limit the pricing of new drugs. Other studies have found that competition between brands depends on the relative quality of competing drugs and the extent to which they are marketed, newer, safer or more effective drugs, and badociated increased commercialization. at higher intra-clbad catalog prices. According to the authors, the results suggest that policies to promote drug brand competition in the US pharmaceutical market, such as accelerated approval of drugs that are not first in the category, are unlikely to lead to lower price on the list of medicines structural reforms.
Source of the story:
Material provided by PLOS. Note: Content can be changed for style and length.
Source link
